Total Neo-adjuvant therapy
Phase 2
Total Neo-adjuvant therapy is one of 4 therapeutic programs targeting Locally-advanced Rectal Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Locally-Advanced Rectal Cancer
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
PD-1 Inhibitor
Johnson & JohnsonPhase 2
Rsifn-Co
SSichuan Huiyang Life Science and Technology Corporation
Phase 2
Total Neo-adjuvant therapy
SSichuan Huiyang Life Science and Technology Corporation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally-advanced Rectal Cancer1 trial
A Randomized, Multi-Center, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Recombinant Super-Compound Interferon (rSIFN-co) in Combination With Total Neo-adjuvant Therapy, in Subjects With Mid-low Locally Advanced Rectal Cancer
Not yet recruiting·SSichuan Huiyang Life Science and Technology Corporation·Phase 2·NCT07662278·90 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Total Neo-adjuvant therapy. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]